Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
258.95
+9.91 (3.98%)
Oct 8, 2025, 4:00 PM EDT - Market closed
Penumbra Revenue
Penumbra had revenue of $339.46M in the quarter ending June 30, 2025, with 13.38% growth. This brings the company's revenue in the last twelve months to $1.28B, up 12.92% year-over-year. In the year 2024, Penumbra had annual revenue of $1.19B with 12.86% growth.
Revenue (ttm)
$1.28B
Revenue Growth
+12.92%
P/S Ratio
7.81
Revenue / Employee
$284,478
Employees
4,500
Market Cap
10.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PEN News
- 4 hours ago - Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 - PRNewsWire
- 4 weeks ago - Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile - PRNewsWire
- 5 weeks ago - Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Penumbra, Inc. Names Shruthi Narayan as Company President - PRNewsWire
- 7 weeks ago - Penumbra, Inc. to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 2 months ago - Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference - PRNewsWire